United Therapeutics (UTHR) news
Recent news
United Therapeutics: PDUFA target action date June 24, 2027
United Therapeutics Corporation (Nasdaq: UTHR) has a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, for a pending FDA review. This date marks the deadline by which the U.S. Food and Drug Administration is expected to complete its evaluation of the company’s submission,…
AInvest Wire · 7d agoUnited Therapeutics Corporation: Ralinepag has not been approved for use in any indication by FDA and remains investigational for PAH
AInvest Wire · 7d agoUnited Therapeutics announces FDA filing acceptance of NDA for
United Therapeutics Corporation (Nasdaq: UTHR) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a clinical trial of its investigational UKidney™, a 10 gene-edited source pig . This marks the first-ever human clinical…
AInvest Wire · 7d agoUnited Therapeutics Corporation - FDA sets PDUFA target action date for ralinepag on June 24, 2027
AInvest Wire · 7d agoUnited Therapeutics Corporation - topline data from Teton-PPF study expected in second half of 2027
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.